Table 7:
Expected Number in Target Population in the Next 5 Years in Ontario
| Expected Number of Patients | |||||
|---|---|---|---|---|---|
| Type of Treatment Method | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 |
| Total immunodeficiency patients treated with IVIG or SCIG | 1,143 | 1,234 | 1,333 | 1,440 | 1,555 |
| Reference scenario: current uptake rate of SCIG | 22% | 22% | 22% | 22% | 22% |
| SCIG (adults and children) | 248 | 268 | 289 | 312 | 337 |
| Adult patients (88%) | 218 | 236 | 254 | 275 | 297 |
| Pediatric patients (12%) | 30 | 32 | 35 | 37 | 40 |
| IVIG (adults and children) | 895 | 966 | 1,044 | 1,128 | 1,218 |
| Adult patients (88%) | 788 | 850 | 919 | 993 | 1,072 |
| Pediatric patients (12%) | 107 | 116 | 125 | 135 | 146 |
| New Scenario: increased uptake rate of SCIG | 43% | 50% | 57% | 64% | 70% |
| SCIG (adults and children) | 491 | 617 | 760 | 922 | 1,089 |
| Adult patients (88%) | 432 | 543 | 669 | 811 | 958 |
| Pediatric patients (12%) | 59 | 74 | 91 | 111 | 131 |
| IVIG (adults and children) | 652 | 617 | 573 | 518 | 466 |
| Adult patients (88%) | 574 | 543 | 504 | 456 | 410 |
| Pediatric patients (12%) | 78 | 74 | 69 | 62 | 56 |
Abbreviations: IVIG, intravenous immunoglobulin; SCIG, subcutaneous immunoglobulin.